Search

Your search keyword '"Pierre Kieffer"' showing total 22 results
Start Over Author "Pierre Kieffer"
22 results on '"Pierre Kieffer"'

1. Value of PCR, Serology, and Blood Smears for Human Granulocytic Anaplasmosis Diagnosis, France

Author

Yves Hansmann, Benoit Jaulhac, Pierre Kieffer, Martin Martinot, Elisabeth Wurtz, Régis Dukic, Geneviève Boess, André Michel, Christophe Strady, Jean François Sagez, Nicolas Lefebvre, Emilie Talagrand-Reboul, Xavier Argemi, and Sylvie De Martino

Subjects
Anaplasma phagocytophilum, anaplasmosis, tickborne diseases, PCR, serology, blood smears, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

We prospectively examined the effectiveness of diagnostic tests for anaplasmosis using patients with suspected diagnoses in France. PCR (sensitivity 0.74, specificity 1) was the best-suited test. Serology had a lower specificity but higher sensitivity when testing acute and convalescent samples. PCR and serology should be used in combination for anaplasmosis diagnosis.

Published
2019
Full Text
View/download PDF

2. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France[S]

Author

René Wintjens, Dominique Bozon, Khaldia Belabbas, Félicien MBou, Jean-Philippe Girardet, Patrick Tounian, Mathilde Jolly, Franck Boccara, Ariel Cohen, Alexandra Karsenty, Béatrice Dubern, Jean-Claude Carel, Ahlam Azar-Kolakez, François Feillet, François Labarthe, Anne-Marie Colin Gorsky, Alice Horovitz, Catherine Tamarindi, Pierre Kieffer, Anne Lienhardt, Olivier Lascols, Mathilde Di Filippo, and Fabienne Dufernez

Subjects
familial hypercholesterolemia, apolipoproteins, apolipoprotein E, cholesterol, low density lipoprotein, phenotype/genotype correlation, Biochemistry, QD415-436
Abstract

Autosomal dominant hypercholesterolemia (ADH) is a human disorder characterized phenotypically by isolated high-cholesterol levels. Mutations in the low density lipoprotein receptor (LDLR), APOB, and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes are well known to be associated with the disease. To characterize the genetic background associated with ADH in France, the three ADH-associated genes were sequenced in a cohort of 120 children and 109 adult patients. Fifty-one percent of the cohort had a possible deleterious variant in LDLR, 3.1% in APOB, and 1.7% in PCSK9. We identified 18 new variants in LDLR and 2 in PCSK9. Three LDLR variants, including two newly identified, were studied by minigene reporter assay confirming the predicted effects on splicing. Additionally, as recently an in-frame deletion in the APOE gene was found to be linked to ADH, the sequencing of this latter gene was performed in patients without a deleterious variant in the three former genes. An APOE variant was identified in three patients with isolated severe hypercholesterolemia giving a frequency of 1.3% in the cohort. Therefore, even though LDLR mutations are the major cause of ADH with a large mutation spectrum, APOE variants were found to be significantly associated with the disease. Furthermore, using structural analysis and modeling, the identified APOE sequence changes were predicted to impact protein function.

Published
2016
Full Text
View/download PDF

3. Small bowel involvement documented by capsule endoscopy in Churg-Strauss syndrome

Author

Birane Beye, Gilles Lesur, Pierre Claude, Lionel Martzolf, Pierre Kieffer, and Daniel Sondag

Subjects
churg-strauss syndrome, small intestine involvement, video capsule endoscopy, Medicine
Abstract

Churg-Strauss syndrome is a small and medium vessel vasculitis and is also known as allergic granulomatous angiitis. Gastrointestinal involvement is common in patients with Churg-Strauss syndrome (20-50%). The most common symptoms are abdominal pain, diarrhoea and occasionally gastrointestinal bleeding and perforation. We present a case of Churg-Strauss syndrome with small bowel lesions documented by video capsule endoscopy.

Published
2015
Full Text
View/download PDF

4. Association entre la Maladie cœliaque et la Cardiomyopathie dilatée: Association between Celiac disease and Dilated cardiomyopathy

Author

Mahavivola, Ernestho-ghoud Indretsy, Sitraka, Rasolonjatovo Anjaramalala, and Pierre, Kieffer

Subjects
Celiac disease, Dilated cardiomyopathy, Morbidity Association
Abstract

Celiac disease (CD) associated to the dilated cardiomyopathy (DCM) has been rarely reported. The influence of the association between CD and DCM remains unexplained. Its evolution is just unpredictable. So, we aimed to report a case that illustrates interactions between CD and DCM. The case consists of a 61-year-old French woman who developed dermatitis herpetiformis treated during 1983 (20 years) by Dapsone and without the gluten-free diet. In 2013, subsequent investigation into her dermatitis herpetiformis revealed a new diagnosis of CD, an osteoporosis and low level of carnitine. Before that, in 2010, cardiac investigations showed a severely dilated left ventricle with an ejection fraction of 25%, due to DCM. These two diseases were considered unrelated and their coexistence was attributed to independent antitissue transglutaminase antibodies, low carnitine level and osteoporosis processes. Howether, CD with osteoporosis and DCM are common conditions associated with significant morbidity, mortality and disability, which requires multidisciplinary approach. La maladie cœliaque (MC) était rarement associée à la cardiomyopathie dilatée (CMD). La physiopathologie exacte de cette association est encore mal élucidée. Son évolution était aussi imprévisible. Notre objectif était de décrire l’interaction entre la MC et la CMD. Nous rapportons une patiente Française âgée de 61 ans, présentant une dermatite herpétiforme traitée de façon symptomatique depuis 1983 (soit 20 ans) par Dapsone. En 2013, le bilan de la dermatite herpétiforme confirmait la MC, une ostéoporose et un déficit en carnitine. Avant cela, en 2010, le bilan cardiologique avait documenté une CMD avec une fraction d’éjection ventriculaire gauche effondrée à 25%. Ces deux pathologies étaient considérées comme indépendantes et leur coexistence était attribuée à des processus indépendants liés aux anticorps antitransglutaminases, déficit en carnitine et l’ostéoporose. Cependant, la MC et l’ostéoporose avec la CMD sont des affections courantes associées à une morbidité, mortalité et une invalidité importante, nécessitant une approche multidisciplinaire.&nbsp

Published
2021

5. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Author

Jérôme Avouac, Elodie Drumez, Eric Hachulla, Raphaèle Seror, Sophie Georgin-Lavialle, Soumaya El Mahou, Edouard Pertuiset, Thao Pham, Hubert Marotte, Amélie Servettaz, Fanny Domont, Pascal Chazerain, Mathilde Devaux, Pascal Claudepierre, Vincent Langlois, Arsène Mekinian, Alexandre Thibault Jacques Maria, Béatrice Banneville, Bruno Fautrel, Jacques Pouchot, Thierry Thomas, René-Marc Flipo, Christophe Richez, Florence Aeschlimann, Christian Agard, Nassim Ait-Abdallah, Jean-David Albert, Didier Alcais, Jean-Sébastien Allain, Yannick Allanore, Blanca Amador-Borreiro, Zahir Amoura, Emma Andre, Anaïs Arbault, Jean-Benoît Arlet, Laurent Arnaud, Denis Arniaud, Herliette Arty-Hue, Lucie Atlan, Alexandra Audemard-Verger, Christine Audoin-Pajot, Victor Audren, Maxime Bach-Bunner, Hélène Bacquet-Deschryver, Brigitte Bader-Meunier, Nathalie Balandraud, Jean-Charles Balblanc, Stéphane Bally, Frédéric Banal, Pierre Barbery, Thomas Barnetche, Audre Barrelet, André Basch, Vincent Baumier, Guillaume Bayer, Sophie Bayle, Catherine Beauvais, Rudie Beinat, Véronique Belin, Rakiba Belkhir, Ruben Benainous, Alexandre Belot, Mohammed Benammar, Mathilde Benhamou, Ygal Benhamou, Ahmed Benmansour, Pascal Bennet, Brigitte Bernoux-Manat, Elise Berthet, Emilie Berthoux, Ewa Bertolini, Adrien Bigot, Aurélia Bisson-Vaivre, Gilles Blaison, Gilles Bolla, Olivier Bonidan, Christine Bonnet, Raphaël Borie, Marie Bossert, Laurence Boudou, Françoise Bouhour, Kévin Bouiller, Bastien Bouldoires, Karima Boussoualim, Eric Bouvard, Regine Brondino, Pierre Buchlin, Laurence Cabantous, Patrice Cacoub, Simon Cadiou, Maurizio Carteni, Aurélia Carbasse, Brice Castel, Pascal Cathebras, Hervé Caumont, Annalisa Celant, Benjamin Chaigne, Benoît Chaillous, Romuald Champy, Agnès Charcot, Pierre Charles, Isabelle Charlot-Lambrecht, Caroline Charpin, Emmanuel Chatelus, Bernard Chaudier, Pascale Chertok, Xavier Chevalier, Maxime Chevreau, Emilie Chotard, Delphine Chu Miow Lin, Gaëlle Clavel, Cyril Clavel-Osorio, Fleur Cohen, Gregory Cohen, Marie-Eve Colette-Cedoz, Nived Collercandy, Antoine Colombey, Chloé Comarmond, Bernard Combe, Céline Comparon, Elodie Constant, Pascal Coquerelle, Justine Corli, Clémence Corre, Nathalie Costedoat-Chalumeau, Marie Couret, Natacha Courvoisier, Fabienne Coury-Lucas, Cécile Coutarel, Fabrice Coutier, Richard Damade, Laurence Daver-Malaterre, Sarahe Dehimat, Michel Delahousse, Emilie Barrois-Delattre, Delphine Denarie, Camille Deprouw, Emanuelle Dernis, Alban Deroux, Renaud Desbarbieux, Elise Descamps, Chantal Deslandre, Marie Desmurs, Jacques Despaux, Marie Desplats, Frédérick Detree, Valérie Devauchelle-Pensec, Robin Dhote, Philippe Dieude, Yannick Dieudonne, Elisabeth Diot, Guillaume Direz, Djamal-Dine Djeddi, Sarah Douvier, Béatrice Drouet, Catherine Duc, Angélique Ducornet, Carine Dufauret-Lombard, Alain Duhamel, Cécile Dumaine, Anne-Elisabeth Dumel, Chantal Dumoulin-Richez, Agnès Duquesne, Géraldine Durand, Mariane Durandin-Truffinet, Pierre-Marie Duret, Maïka Duval, Mikaël Ebbo, Esther Ebstein, Andra Economu-Dubosc, Stéphanie Emilie, Romain Euvrard, Philippe Evon, Sylvie Fabre, Dorothée Fagedet, Meryem Farhat, Marion Fauconier, Jacques Fechtenbaum, Renaud Felten, Fanny Fernandes, Nicole Ferreira-Maldent, Elodie Feurer, Amandine Fichet, Françoise Flaisler, Nans Florens, Violaine Foltz, Elisabeth Fontanges, Jennifer Foret, Anne-Claire Fougerousse, Anne Fouque-Aubert, Catherine Foutrier-Morello, Hélène Francois-Pradier, Léa Frantzen, Pierre Fritz, Antoine Froissart, Jean Fulpin, Piera Fuzibet, Francis Gaches, Laurence Gagneux-Lemoussu, Mélanie Penhoat-Gahier, Joris Galland, Frédérique Gandjbakhch, Nicole Garnier, Thomas Garraud, Jean-François Garrot, Romain Gastaldi, Véronique Gaud-Listrat, Maud Gauthier-Prieur, Dana Georgescu, Nathalie Gerard, Elisabeth Gervais, Christelle Gibert, Eric Gibert, Ghislaine Gill, Jérôme Gillard, Mélanie Gilson, Pauline Gimonnet, Jeanine-Sophie Giraudet-Le Quintrec, Aude Giraud-Morelet, Baptiste Glace, Camille Glanowski, Bertrand Godeau, Bruno Gombert, Camille Gonnet-Gracia, Tiphaine Goulenok, Philippe Goupille, Olivier Gourmelen, Sophie Govindaraju-Audouard, Franck Grados, Martine Grall-Lerosey, Bruno Grardel, Anne Grasland, Gilles Grateau, Monica Groza, Constance Guillaud, Séverine Guillaume, Caroline Guillibert, Xavier Guillot, Philippe Guilpain, Aline Gury, Marie-Hélène Guyot, Cécile Hacquard-Bouder, Marie-Noelle Havard, Jean-Pierre Hellier, Pascal Hennequin, Basile Henriot, Julien Henry, Véronique Hentgen, Marion Hermet, Muriel Herasse, Julie Hernandez, Miguel Hie, Pascal Hilliquin, Olivier Hinschberger, Ambre Hittinger-Roux, Jan Holubar, Christophe Hudry, Serge Huguenel, Clara Jaccard, Jean-Michel, Jacquemier, Bénédicte Jamard, Catherine Jan, Sylvie Jean, Mathieu Jouvray, Pierre-Antoine Juge, Laurent Juillard, Denis Jullien, Anna Kabala, Abdelkrim Kabchou, Ludovic Karkowski, Françoise Karman, Farid Kemiche, Jérémy Keraen, Pierre Kieffer, Isabelle Kone-Paut, Abdeldajallil Koreichi, Marie Kostine, Sylvain La Batide Alanore, Pierre Lafforgue, Sophie Lahalle, Marc Lambert, Isabelle Lambrecht, Sylvain Lanot, Aurélia Lanteri, Jean-Paul Larbre, Augustin Latourte, Christian Lavigne, Sophie Le Guen Guegan, Guillaume, Le Guenno, Diane Leguy, Agnès Lebrun, Emmanuel Ledoult, Nathalie Legoupil, Erick Legrand, Charlotte Lejeune, Olivier Leloire, Christophe Leroux, Rémi Leroy, Marie Leroy-Gouix, Tifenn Leturcq, Amélie Leurs, Céline Leveque-Michaud, François-Xavier Limbach, Frédéric Liote, Anne Lohse, Pierre Lozac'h, Virginie Lucas, Aurélie Madelon, Nadine Magy-Bertrand, Matthieu Mahevas, Hélène Maillard, Thibault Maillet, Sandrine Malochet-Guinamand, Quentin Mangon, Sylvie Marchou-Lopez, Nathalie Margarit, Thierry Marhadour, Xavier Mariette, Claire Martin, Alexis Mathian, François Maurier, Frédéric Maury, Betty Mazet-Guillaume, Arnaud Mazouyez, Hassan Mazyad, Nadia Mehsen-Cetre, Ulrich Meinzer, Isabelle Melki, Laurent Messer, Corinne Miceli, Martin Michaud, Catherine Michel, Matthias Michel, Mathilde Michon, Anne-Marie Milesi-Lecat, Anna Molto, Marie Moly, Olivier Moranne, Gautier Morel, Hugo Morel, Jacques Morel, Franck Morin, Laurence Moulinier, Guillaume Moulis, Bertrand Moura, Minh Nguyen, Sabine Nicolas-Vullierme, Hubert Nielly, Gaétane Nocturne, Aurore Nottez, Henri-Olivier Ollagnon, Isabelle Pacaud-Vitoux, Anne Pagnier, Caroline Paris, Antoine Parrot, Tristan Pascart, Yasmina Pascaud-Mansour, Lætitia Paulin, Stephan Pavy, Laurent Perard, Yves-Marie Pers, Micheline Pha, Maud Pichon, Audrey Pierreisnard, Gabrielle Pizana, Sylvaine Poignant, Elsa Poix, Agnès Portier, Antoine Poulet, Samira Plassard, Grégory Pugnet, Déborah Puyraimond-Zemmour, Pierre Quartier-Dit-Maire, Marion Quenet, Viviane Queyrel, Loïc Raffray, Philippe Remy, Myriam Renard, Jessica Rene, Sabine Revuz, Bénédicte Rey, Gaëlle Richard-Colmant, Etienne Riviere, Sébastien Riviere, Sophie Robin, Julien Rohmer, Isabelle Roitg, Mélanie Romier, Michel Rolland, Mélanie Roriz, Carole Rosenberg, Linda Rossi, Olivier Roth, Sid-Ahmed Rouidi, Mathilde Roumier, Mickaël Rousiere, Clémentine Rousselin, Bénédicte Rouviere, Christian Roux, Fabienne Roux, Marielle Roux, Nicolas Roux, Diane Rouzaud, Sylvie Rozenberg, Isabelle Sacco, Fatiha Sadji, Laurent Sailler, Carine Salliot, Jean-Hugues Salmon, Alain Saraux, Jean Schmidt, Julie Seguier, Jérémie Sellam, Eric Senbel, Thomas Sene, Patricia Senet, Pascal Seve, Aurélie Sicaud, Perrine Smets, Vincent Sobanski, Christelle Sordet, Elisabeth Sornay-Rendu, Odile Souchaud-Debouverie, Lætitia Sparsa, Lionel Spielmann, Sarah Steib, Chloé Stavris, Catherine Straus, Victor Strotz, Paulina Szafors, Séverine Taffignon-Clave, Justine Simoens, Claire Theillac, Nora Tenenbaum, Benoît Thomachot, Nathalie Tieulie, Soizic Tiriau, Alice Tison, Eric Toussirot, Ludovic Trefond, Sophie Trijau, Sébastien Trouillier, Anne-Priscille Trouvin, Marie-Elise Truchetet, Marc Ulrich, Jacques Vaquier, Eric Veillard, Laurent Veillon, Guillaume Vial, Jean-François Viallard, Judith Victor, Claire Vidon, Mathias Vidon, Camille Vigne, Alexandre Virone, Ursula Warzocha, Daniel Wendling, Claude Werle, Cécile Wibaux, Alexandra Willems, Michel Wisniewski, Juliette Woessner, Bernadette Xerri-Campano, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Tourcoing, Centre Hospitalier René Dubos [Pontoise], Assistance Publique - Hôpitaux de Marseille (APHM), Santé Ingénierie Biologie Saint-Etienne (SAINBIOSE), Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie Intégrative du Tissu Osseux (LBTO), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique - Epidémiologie Clinique Saint-Etienne (CIC-EC), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Groupe Hospitalier Diaconesses Croix Saint-Simon, Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Saint-Antoine [AP-HP], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), CHU Bordeaux [Bordeaux], Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie intégrative du tissu osseux, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Saint Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Nord (Saint Etienne), centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Service de rhumatologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de rhumatologie [CH Gustave Dron, Tourcoing], Centre Hospitalier Gustave Dron [Tourcoing], Hopital Réné Dubos, Université Paris 1 Panthéon-Sorbonne - UFR Science Politique (UP1 UFR11), and Université Paris 1 Panthéon-Sorbonne (UP1)

Subjects
medicine.medical_specialty, Immunology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, immune system diseases, law, hemic and lymphatic diseases, Internal medicine, Clinical endpoint, Immunology and Allergy, Medicine, 030212 general & internal medicine, 030203 arthritis & rheumatology, business.industry, Hazard ratio, Odds ratio, Articles, medicine.disease, Intensive care unit, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Rheumatoid arthritis, Cohort, Rituximab, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cohort study, medicine.drug
Abstract

Summary Background Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases. Methods In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609. Findings Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66–6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46–0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55–3·19, p=0·53). Interpretation Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases. Funding None.

Published
2021

6. Contribution of an Early Internal Medicine Rotation to the Clinical Reasoning Learning for Young Residents

Author

A. Purcarea, Cécile Goujard, Anne Bourgarit, Pierre Kieffer, Silvia Sovaila, Brigitte Granel, Antoine Froissart, Jean-Christophe Weber, Jean-François Bergmann, Brigitte Ranque, Stephane Gayet, and Emmanuel Andrès

Subjects
medicine.medical_specialty, 020205 medical informatics, Concordance, education, Specialty, Script Concordance Tests, 02 engineering and technology, 03 medical and health sciences, 0302 clinical medicine, internal medicine rotation, Internal medicine, 0202 electrical engineering, electronic engineering, information engineering, medicine, Internal Medicine, Humans, Learning, 030212 general & internal medicine, Competence (human resources), Clinical reasoning, Significant difference, Medical practice, Internship and Residency, General Medicine, Original Article, Clinical Competence, Educational Measurement, Psychology, residency
Abstract

Clinical reasoning is the cornerstone of medical practice, and achieving this competence depends on a large number of factors. Internal medicine departments provide junior doctors with plentiful and varied patients, offering a comprehensive basis for learning clinical reasoning. In order to evaluate the usefulness of an early rotation at internal medicine departments, we compared, via script concordance tests, the evolution of residents’ clinical reasoning after an initial internal medicine rotation compared to rotations through other medical specialties. Twenty-two residents were tested after six months of their internal medicine rotation and compared to twenty-five residents that had the first rotation in another specialty (control). We showed a significant difference in the improvement of the script concordance tests scores (p=0.015) between the beginning and the end of their first rotation between the internal medicine and the control groups, and this implies the lower improvement of clinical reasoning skills and spontaneous learning slope of the junior doctors in other departments.

Published
2020

7. Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis

Author

Jean-Christophe Weber, Vincent Poindron, Jean-Loup Pennaforte, Gilles Blaison, Denis Wahl, C. Martinez, Nadine Magy-Bertrand, Philip Bielefeld, Pierre Kieffer, Bernard Bonnotte, Hervé Devilliers, Sabine Berthier, Thierry Martin, Laurent Arnaud, Mickael Martin, François Maurier, Médecine interne [ Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Médecine interne [Hôpitaux civils de Colmar], Hôpitaux Civils de Colmar, Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre National de Référence pour les Maladies Auto-immunes Rares [CHU Strasbourg] (RESO), CHU Strasbourg, Médecine interne [CHU Strasbourg], Département de Médecine Interne et Immunologie Clinique (DMIIC - STRASBOURG), Médecine interne [CH Emile Muller, Mulhouse], Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA)-Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Service de médecine interne et immunologie clinique (SOC 1) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Médecine Interne et Vasculaire [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre régional de compétence des Maladies systémiques et auto-immunes rares de l'adulte et Maladies vasculaires rares, Faculté de Médecine [Nancy], Université de Lorraine (UL), Service de Médecine Interne [CHR Metz-Thionville], Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Rhumatologie [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Service de médecine interne (Med Int - BESANCON), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and WEBER, JEAN-CHRISTOPHE

Subjects
Male, Raynaud’s phenomenon, 0302 clinical medicine, Risk Factors, Informed consent, Immunology and Allergy, Medicine, 030212 general & internal medicine, skin and connective tissue diseases, ComputingMilieux_MISCELLANEOUS, Gangrene, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, integumentary system, biology, antiphospholipid antibodies, Interstitial lung disease, Middle Aged, Pathophysiology, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antibodies, Antiphospholipid, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Disease Susceptibility, Antibody, Adult, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Immunology, digital ulcer, Systemic Sclerosis, Fingers, 03 medical and health sciences, Rheumatology, Antiphospholipid syndrome, Internal medicine, Skin Ulcer, Humans, Aged, Autoantibodies, 030203 arthritis & rheumatology, Autoimmune disease, Scleroderma, Systemic, business.industry, medicine.disease, Cross-Sectional Studies, biology.protein, business, antiphospholipid syndrome, Biomarkers
Abstract

Key messages #### What is already known about this subject? #### What does this study add? #### How might this impact on clinical practice? Raynaud’s phenomenon (RP) in systemic sclerosis (SSc) can be severe with active digital ulceration (ADU) and gangrene. RP physiopathology includes early endothelial cell injury, vascular dysfunction and sometimes microvascular thrombosis.1 Antiphospholipid antibodies (aPL) activate endothelial cells and platelets by complexes of beta-2 glycoprotein 1 (β2GP1) and anti-β2GP12 and could therefore contribute to the initiation of and/or aggravate SSc-related RP. aPL prevalence seems increased in patients with SSc compared with controls,3 but aPL-associated clinical features are often contradictory. The aims of this study were to assess aPL and antiphospholipid syndrome (APS) prevalence in patients with SSc and their association with ADU. Consecutive patients aged more than 18 years, fulfilling the American College of Rheumatology/EULAR classification criteria for SSc4 and followed in seven French expert centres for autoimmune diseases labelled by the French national network for autoimmune disease care, were enrolled prospectively during 8 months. Patients with other associated autoimmune disease were excluded. All patients provided written informed consent. SSc subtype was classified based on LeRoy and Medsger’s criteria,5 and skin involvement was assessed according to the modified Rodnan skin score (mRSS).6 Interstitial lung disease …

Published
2019

8. FRI0337 INCIDENCE AND PREVALENCE OF MYOSITIS ASSESSED BY MULTI-SOURCES CAPTURE-RECAPTURE METHODOLOGY

Author

Alain Meyer, Léa Debrut, Thierry Martin, Gilles Blaison, Lionel Spielmann, Jean Sibilia, and Pierre Kieffer

Subjects
medicine.medical_specialty, business.industry, Medical record, Incidence (epidemiology), Prevalence, medicine.disease, Mark and recapture, Family medicine, Health care, Epidemiology, medicine, Referral center, business, Myositis
Abstract

Background Precise epidemiology of myositis epidemiology remains largely unknown (1). Surveys based solely on administrative claims benefit from large case ascertainment but may be influenced by miscoding and misdiagnosing. The use of medical records with charts review benefit from accurate diagnosis but exhaustive ascertainment is difficult to achieve because numerous specialists are involved and cases may concern both inpatients and outpatients. To overcome these difficulties we undertook a capture–recapture survey that takes advantage of a multi-sources case ascertainment to estimate the number of cases missed by any one source and to correct the prevalence rate (2). Objectives To assess the incidence and prevalence of myositis in Alsace, a region of eastern France. Methods Alsace, region of eastern France, is home to about 2 million inhabitants benefiting from high access to healthcare and a labialized referral center for myositis. Seeking care outside is uneasy because of peculiar geography. Myositis patients were retrieved through three separate sources: i) all general practitioners and community specialist ii) Muscle pathology center records, iii) all public and private hospitals records, vi) all public and private laboratory records. Incident and prevalent cases fulfilling the ACR/EULAR criteria for myositis were included. Results The responses to the questionnaires sent to the physicians (n=3452), yielded 105 potential myositis cases. All hospital centres contacted (n=13) participated in the study and 1335 potential myositis patients were recorded by this source. 263 potential myositis cases were identified through muscle pathology center records. 13 laboratories participate in the studies and 324 potential myositis patients were recorded by this source. We thus received 1863 records of suspected myositis after excluding duplicates within each sources. The thorough review of the corresponding medical charts is currently ongoing and at this stage 10% of the potential cases fulfilled the ACR/EULAR criteria for myositis. Conclusion This first study based on a multi-sources capture-recapture methodology and ACR/EULAR criteria is very likely to provide an accurate estimation of myositis epidemiology. References [1] Incidence and prevalence of inflammatory myopathies: a systematic review. [2] Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. [3] Rheumatology (Oxford). 2015;54:50-63. [4] Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region. [5] Meyer A, Chifflot H, Chatelus E, Kleinmann JF, Ronde-Ousteau C, Klein D, Jegu J, Geny B, Hirshi S, Canuet M, Blaison G, Kieffer P, Lipsker D, Martin T, Sauleau E, Velten M, Sibilia J. Arthritis Rheumatol. 2016;68:1731-7. Disclosure of Interests None declared

Published
2019

9. Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region

Author

Erik Sauleau, Pierre Kieffer, J.F. Kleinmann, Gilles Blaison, Jérémy Jégu, Hélène Chifflot, Bernard Geny, Emmanuel Chatelus, Sandrine Hirshi, Thierry Martin, Alain Meyer, Cécile Ronde-Ousteau, Jean Sibilia, Michel Velten, Dan Lipsker, Delphine Klein, and Matthieu Canuet

Subjects
030203 arthritis & rheumatology, medicine.medical_specialty, Pathology, education.field_of_study, business.industry, Immunology, Population, Prevalence, Confidence interval, Spatial heterogeneity, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Statistical significance, Health care, Epidemiology, medicine, Immunology and Allergy, 030212 general & internal medicine, Young adult, business, education, Demography
Abstract

Objective Alsace is a region in eastern France with a population of ∼2 million. All residents have high access to health care and an accredited referral center for SSc. Seeking care outside of this region is difficult because of the peculiar geography. The aim of this study was to assess the prevalence and spatial variation of systemic sclerosis (SSc) in eastern France. Methods Data for SSc patients were obtained from 3 sources (all general practitioners and community specialists, capillaroscopy centers, and all public and private hospital records) and were used to estimate the prevalence of SSc. Surviving patients who resided in Alsace on January 1, 2008 and fulfilled the American College of Rheumatology and/or the LeRoy and Medsger criteria were included in this study. The clinical characteristics of the patients were also assessed. Potentially incomplete case ascertainment was corrected by capture–recapture analyses. Geographic disparities were assessed by spatial cluster analysis and by comparing our results with those for other geographic areas in the world for which data derived using similar methodology were available. Results The review of 499 potential cases identified a total of 244 SSc patients. A trend toward a west-to-east gradient was observed but did not reach statistical significance. According to log-linear modeling, an estimated 83.87 additional cases were missed. Thus, the SSc prevalence was 228.42 cases per million adult inhabitants of Alsace (95% confidence interval 203.70–253.14); this prevalence was significantly higher than that in 2 other regions of France and comparable with the reported prevalence in Detroit, Michigan. Conclusion The stringent methodology used in the current study is very likely to provide an accurate estimation of the prevalence of SSc. Design similarity with 3 other surveys extends the scope of the results by identifying geographic disparities that were previously indistinguishable due to methodologic differences.

Published
2016

10. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France

Author

Pierre Kieffer, Jean-Philippe Girardet, Khaldia Belabbas, Anne Lienhardt, Ahlam Azar-Kolakez, François Labarthe, Anne-Marie Colin Gorsky, Olivier Lascols, Béatrice Dubern, Franck Boccara, Catherine Tamarindi, Mathilde Di Filippo, Jean-Claude Carel, Félicien MBou, Alice Horovitz, René Wintjens, Dominique Bozon, Mathilde Jolly, Fabienne Dufernez, Ariel Cohen, François Feillet, Patrick Tounian, A. Karsenty, Université Libre de Bruxelles [Bruxelles] (ULB), Centre de Biologie et Pathologie Est (CBPE), Hospices Civils de Lyon (HCL)-Centre National de Référence des Légionelles, Laboratoire Commun de Biologie et Génétiques Moléculaires (LCBGM [Hôpital Saint-Antoine]), AP-HP - Hôpital Saint-Antoine, Service d’Endocrinologie [Hôpital le Lamentin Bourg - CHU de la Martinique], CHU de la Martinique [Fort de France]-Hôpital Le Lamentin Bourg [CHU de la Martinique], CHU de la Martinique [Fort de France], Service de Gastroentérologie et Nutrition Pédiatrique [APHP Trousseau], CHU Trousseau [APHP], Service d'Endocrinologie, Diabétologie et Nutrition [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Cardiologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Service d'endocrinologie diabétologie pédiatrique [CHU Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Centre de Référence des Maladies Endocriniennes Rares de la Croissance [APHP Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Médecine Infantile III et Génétique Clinique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine pédiatrique [CHRU Tours-Clocheville], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre Hospitalier d'Argenteuil, Service de Cardiologie [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de Maternité [CHU Hagueneau], Centre Hospitalier Hagueneau (CH Hagueneau), Service de Médecine Interne [CH Mulhouse- E. Muller], Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA)-Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Université libre de Bruxelles (ULB), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Victor Dupouy, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biology-Imaging District of East-Hospitals Group of AP-HP (Assistance Publique-Hopitaux de Paris), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
Male, Models, Molecular, Protein Conformation, alpha-Helical, 0301 basic medicine, Apolipoprotein E, Genotyping Techniques, Apolipoprotein B, Familial hypercholesterolemia, apolipoprotéine, 030204 cardiovascular system & hematology, medicine.disease_cause, Biochemistry, Cohort Studies, Exon, 0302 clinical medicine, Endocrinology, Child, apolipoprotein E, Genetics, Mutation, familial hypercholesterolemia, biology, cholestérol, Exons, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Endocrinologie, 3. Good health, phénotype, Phenotype, Kexin, Female, lipids (amino acids, peptides, and proteins), France, Proprotein Convertase 9, génotype, corrélation, Adult, Biochimie, hypercholestérolemie, QD415-436, Hyperlipoproteinemia Type II, Young Adult, 03 medical and health sciences, Apolipoproteins E, apolipoproteins, cholesterol, low density lipoprotein, phenotype/genotype correlation, medicine, Humans, Apolipoproteins B, PCSK9, Cell Biology, medicine.disease, 030104 developmental biology, Receptors, LDL, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, LDL receptor, biology.protein, Biologie cellulaire, Patient-Oriented and Epidemiological Research
Abstract

Autosomal dominant hypercholesterolemia (ADH) is a human disorder characterized phenotypically by isolated high-cholesterol levels. Mutations in the low density lipoprotein receptor ( LDLR ), APOB, and proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) genes are well known to be associated with the disease. To characterize the genetic background associated with ADH in France, the three ADHassociated genes were sequenced in a cohort of 120 children and 109 adult patients. Fifty-one percent of the cohort had a possible deleterious variant in LDLR, 3.1% in APOB, and 1.7% in PCSK9. We identifi ed 18 new variants in LDLR and 2 in PCSK9. Three LDLR variants, including two newly identifi ed, were studied by minigene reporter assay confi rming the predicted effects on splicing. Additionally, as recently an in-frame deletion in the APOE gene was found to be linked to ADH, the sequencing of this latter gene was performed in patients without a deleterious variant in the three former genes. An APOE variant was identifi ed in three patients with isolated severe hypercholesterolemia giving a frequency of 1.3% in the cohort. Therefore, even though LDLR mutations are the major cause of ADH with a large mutation spectrum, APOE variants were found to be signifi-cantly associated with the disease. Furthermore, using structural analysis and modeling, the identifi ed APOE sequence changes were predicted to impact protein function., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2016

11. Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations

Author

Aurore, Meyer, Aurélien, Guffroy, Gilles, Blaison, Yannick, Dieudonne, Zahir, Amoura, Bernard, Bonnotte, Christoph, Fiehn, Pierre, Kieffer, Hannes Martin, Lorenz, Nadine, Magy-Bertrand, François, Maurier, Jean-Louis, Pennaforte, Hans-Hartmut, Peter, Andreas, Schwarting, Jean, Sibilia, Laurent, Arnaud, Thierry, Martin, Reinhard Edmund, Voll, Anne-Sophie, Korganow, R, Voll, CHU Strasbourg, Université de Strasbourg (UNISTRA), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Médecine interne [Hôpitaux civils de Colmar], Hôpitaux Civils de Colmar, Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Heidelberg University Hospital [Heidelberg], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpitaux Privés de Metz (HPMetz), Centre Hospitalier Universitaire de Reims (CHU Reims), University of Freiburg [Freiburg], Les Hôpitaux Universitaires de Strasbourg (HUS), and LBBR/Rarenet group: Z Amoura, L Arnaud, G Blaison, B Bonnotte, E Chatelus, E Ciobanu, F Duchene, J P Faller, A Gorse, J E Gottenberg, O Hinschberger, F Jaeger, P Kieffer, M Kilifa, N Magy-Bertrand, T Martin, L Martzolff, F Maurier, A Meyer, J-L Pasquali, J-L Pennaforte, V Poindron, S Revuz, M Samson, J Sibilia, C Sordet, A Theulin, D Wahl, J C Weber, M Bartsch, N Bartholomä, C Fiehn, S Finzel, A Funkert, M Hausberg, H Lorenz, R Max, H-H Peter, M Rizzi, A Schwarting, J Thiel, N Venhoff, R Voll

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, Neutropenia, autoantibodies, Immunology, Disease, Sciences du Vivant [q-bio]/Médecine humaine et pathologie, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, Germany, Lymphopenia, lupus erythematosus, systemic, Internal medicine, medicine, Humans, Oral ulcers, 030203 arthritis & rheumatology, Autoimmune disease, Systemic lupus erythematosus, Genetic heterogeneity, business.industry, Autoantibody, Complement C3, General Medicine, systemic, medicine.disease, Thrombocytopenia, Epidemiology and Outcomes, 3. Good health, Cross-Sectional Studies, Sjogren's Syndrome, 030104 developmental biology, Antibodies, Antinuclear, Case-Control Studies, Cohort, Absolute neutrophil count, Female, France, business, lupus erythematosus, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

ObjectiveSystemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. Neutropaenia is a frequent event in SLE occurring in 20%–40% of patients depending on the threshold value of neutrophil count. On a daily basis, the management of neutropaenia in SLE is difficult with several possible causes. Moreover, the infectious consequences of neutropaenia in SLE remain not well defined.Methods998 patients from the Lupus BioBank of the upper Rhein (LBBR), a large German and French cohort of patients with SLE, mostly of Caucasian origin (83%), were included in this study. Neutropaenia was considered when neutrophil count was below 1800×106/L. An additional analysis of detailed medical records was done for 65 LBBR patients with neutropaenia.Results208 patients with neutropaenia (21%) were compared with 779 SLE patients without neutropaenia. Neutropaenia in SLE was significantly associated with thrombocytopaenia (OR 4.11 (2.57–10.3)), lymphopaenia (OR 4.41 (2.51–11.5)) and low C3 (OR 1.91 (1.03–4.37)) in multivariate analysis. 65 representative patients with neutropaenia were analysed. Neutropaenia was moderate to severe in 38%, chronic in 31%, and both severe and chronic in 23% of cases. Moderate to severe and chronic neutropaenia were both associated with lymphopaenia and thrombopaenia. Chronic neutropaenia was also associated anti-Ro/SSA antibodies and moderate to severe neutropaenia with oral ulcers.ConclusionThis study is to date the largest cohort to describe neutropaenia in SLE. Neutropaenia displays a strong association with other cytopaenias, suggesting a common mechanism. Chronic neutropaenia is associated with anti-Ro/SSA antibodies with or without identified Sjögren’s disease.

Published
2020

12. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature

Author

Rheinardt Voll, Hannes M. Lorenz, Gilles Blaison, Pierre Kieffer, Bernard Bonnotte, Laurent Arnaud, Zahir Amoura, Vincent Poindron, Jean-Loup Pennaforte, Jean Sibilia, Thierry Martin, Pierre Edouard Gavand, Nadine Magy-Bertrand, Hans-Harmut Peter, François Maurier, Andreas Schwarting, and Christoph Fiehn

Subjects
Adult, Male, medicine.medical_specialty, Anxiety, Logistic regression, Severity of Illness Index, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Rheumatology, Interquartile range, Risk Factors, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, Pharmacology (medical), 030212 general & internal medicine, Depression (differential diagnoses), Fatigue, Aged, 030203 arthritis & rheumatology, Systemic lupus erythematosus, Lupus erythematosus, business.industry, Depression, Odds ratio, Middle Aged, medicine.disease, Cohort, Quality of Life, Female, medicine.symptom, business
Abstract

OBJECTIVE Fatigue is reported in up to 90% of patients with SLE. This study was conducted to identify the determinants associated with fatigue in a large cohort of patients with SLE, as well as to provide a systematic review of the literature. METHODS Patients from the Lupus BioBank of the upper Rhein, a large German-French cohort of SLE patients, were included in the FATILUP study if they fulfilled the 1997 ACR criteria for SLE and had Fatigue Scale for Motor and Cognitive Functions scores collected. Multivariate logistic regression analyses were performed to assess the determinants of fatigue and severe fatigue. RESULTS A total of 570 patients were included (89.1% female). The median age was 42 years (interquartile range 25-75: 34-52). The median value of the SAfety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI was 2 (0-4). Fatigue was reported by 386 patients (67.7%) and severe fatigue by 209 (36.7%). In multivariate analyses, fatigue was associated with depression [odds ratio (OR): 4.72 (95% CI: 1.39-16.05), P = 0.01], anxiety [OR: 4.49 (95% CI: 2.60-7.77), P < 0.0001], glucocorticoid treatment [OR: 1.59 (95% CI 1.05-2.41), P = 0.04], SELENA-SLEDAI scores [OR: 1.05 (95% CI: 1.00-1.12) per 1 point increase, P = 0.043] and age at sampling [OR: 1.01 (95% CI: 1.00-1.03) per 1 year increase, P = 0.03]. Severe fatigue was independently associated with anxiety (P < 0.0001), depression (P < 0.0001), glucocorticoid treatment (P = 0.047) and age at sampling (P = 0.03). CONCLUSION Both fatigue and severe fatigue are common symptoms in SLE, and are strongly associated with depression and anxiety. Disease activity and the use of glucocorticoids were also independently associated with fatigue, although more weakly.

Published
2018

13. AB0593 Predictors of fatigue and severe fatigue in a large multicenter international cohort of patients with systemic lupus erythematosus: the fatilup study

Author

J. Sibilia, Reinhard E. Voll, Z. Amoura, Gilles Blaison, A. Schwartzing, Christoph Fiehn, François Maurier, Thierry Martin, P.E. Gavand, N. Magy Bertrand, Laurent Arnaud, H.-M. Lorenz, Pierre Kieffer, B. Bonnote, Vincent Poindron, and Jean-Loup Pennaforte

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, Univariate analysis, Multivariate analysis, Systemic lupus erythematosus, business.industry, medicine.disease, Hospital Anxiety and Depression Scale, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Quality of life, Internal medicine, Cohort, medicine, Anxiety, medicine.symptom, skin and connective tissue diseases, business, Depression (differential diagnoses)
Abstract

Background Fatigue is an important issue in systemic lupus and has a major impact on quality of life of the patients. Data are controversial about the factors associated with this complex symptom.1 Objectives To identify the factors associated with fatigue and severe fatigue in patients with systemic lupus erythematosus (SLE) in a large cohort using a multivariate model to precise the importance of each parameter in this multidimensional symptom. Methods We used the LBBR data base, a German French data base of SLE patients. All patients fulfilled the 1997 ACR criteria for SLE. The Fatigue Scale for Motor and Cognitive Functions (FSMC) was used to assess fatigue and severe fatigue. The depression and anxiety were measured with Hospital Anxiety and Depression Scale (HADS). Tests were performed at sampling. Results A total of 570 patients were included (89.1% female). The median age was 42 years (QR25–75: 34–52). The median value of the SELENA-SLEDAI was 2 (QR25–75: 0–4) and 136 patients had a SELENA-SLEDAI score >6. Fatigue was reported by 386 patients (67.7%) including severe fatigue by 209 (36.7%). In univariate analysis among the individual components of the SLEDAI arthritis (p=0.003) and oral ulcers (p=0.002) were associated with severe fatigue. In multivariate analysis fatigue was strongly associated with anxiety (OR: 4.49 [95%CI: 2.60–7.77], p Severe fatigue was strongly associated with depression (OR:6.87 [95%CI: 3.12–15.11], p Conclusions Fatigue is a common symptom in SLE patients and is strongly associated with anxiety and depression. While remission remains an important therapeutic target, these manifestations should also be taken care of with psychological counselling and pharmacological intervention, when needed. Reference [1] Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus?Lupus. 2012Apr;21(5):465–76 Disclosure of Interest None declared

Published
2018

14. Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region

Author

Alain, Meyer, Hélène, Chifflot, Emmanuel, Chatelus, Jean-François, Kleinmann, Cécile, Ronde-Ousteau, Delphine, Klein, Jérémy, Jégu, Bernard, Geny, Sandrine, Hirshi, Matthieu, Canuet, Gilles, Blaison, Pierre, Kieffer, Dan, Lipsker, Thierry, Martin, Erik, Sauleau, Michel, Velten, and Jean, Sibilia

Subjects
Adult, Aged, 80 and over, Male, Young Adult, Scleroderma, Systemic, Adolescent, Prevalence, Cluster Analysis, Humans, Female, France, Middle Aged, Aged
Abstract

Alsace is a region in eastern France with a population of ∼2 million. All residents have high access to health care and an accredited referral center for SSc. Seeking care outside of this region is difficult because of the peculiar geography. The aim of this study was to assess the prevalence and spatial variation of systemic sclerosis (SSc) in eastern France.Data for SSc patients were obtained from 3 sources (all general practitioners and community specialists, capillaroscopy centers, and all public and private hospital records) and were used to estimate the prevalence of SSc. Surviving patients who resided in Alsace on January 1, 2008 and fulfilled the American College of Rheumatology and/or the LeRoy and Medsger criteria were included in this study. The clinical characteristics of the patients were also assessed. Potentially incomplete case ascertainment was corrected by capture-recapture analyses. Geographic disparities were assessed by spatial cluster analysis and by comparing our results with those for other geographic areas in the world for which data derived using similar methodology were available.The review of 499 potential cases identified a total of 244 SSc patients. A trend toward a west-to-east gradient was observed but did not reach statistical significance. According to log-linear modeling, an estimated 83.87 additional cases were missed. Thus, the SSc prevalence was 228.42 cases per million adult inhabitants of Alsace (95% confidence interval 203.70-253.14); this prevalence was significantly higher than that in 2 other regions of France and comparable with the reported prevalence in Detroit, Michigan.The stringent methodology used in the current study is very likely to provide an accurate estimation of the prevalence of SSc. Design similarity with 3 other surveys extends the scope of the results by identifying geographic disparities that were previously indistinguishable due to methodologic differences.

Published
2015

15. Small bowel involvement documented by capsule endoscopy in Churg-Strauss syndrome

Author

D. Sondag, Pierre Kieffer, P. Claudé, Lionel Martzolf, Birane Beye, and Gilles Lesur

Subjects
Adult, Male, Gastrointestinal bleeding, Abdominal pain, medicine.medical_specialty, Perforation (oil well), Churg-strauss syndrome, Case Report, Capsule Endoscopy, law.invention, Video capsule endoscopy, churg-strauss syndrome, Capsule endoscopy, law, immune system diseases, hemic and lymphatic diseases, small intestine involvement, Intestine, Small, medicine, Humans, cardiovascular diseases, Allergic granulomatous angiitis, lcsh:R5-920, business.industry, lcsh:Public aspects of medicine, lcsh:RA1-1270, General Medicine, medicine.disease, Abdominal Pain, Surgery, respiratory tract diseases, video capsule endoscopy, Churg-Strauss Syndrome, small intestine involvement, video capsule endoscopy, medicine.symptom, Gastrointestinal Hemorrhage, business, Vasculitis, lcsh:Medicine (General)
Abstract

Churg-Strauss syndrome is a small and medium vessel vasculitis and is also known as allergic granulomatous angiitis. Gastrointestinal involvement is common in patients with Churg-Strauss syndrome (20-50%). The most common symptoms are abdominal pain, diarrhoea and occasionally gastrointestinal bleeding and perforation. We present a case of Churg-Strauss syndrome with small bowel lesions documented by video capsule endoscopy.Key words: Churg-Strauss Syndrome, small intestine involvement, video capsule endoscopy

Published
2015

16. [A plea for a chronobiological approach to diabetes mellitus]

Author

Jean-Marie, Wilhelm, Philippe, Thannberger, Régis, Dukic, Aïcha, Derragui, Orlando, Saraceni, and Pierre, Kieffer

Subjects
Blood Glucose, Chronobiology Phenomena, Diabetes Mellitus, Type 2, Humans, Lipids
Abstract

Diabetes mellitus is, in most patients, a multi-metabolic condition disease under fixed standardized conditions. We develop here the advantages of a chronobiological approach, exploring nycthemeral variations in blood pressure, variations in insulin resistance, postprandial changes in blood glucose and postabsorptive variations in blood lipids. Such information can help improve our understanding of the disease, better identify risk and prognosis, and enlighten therapeutic options.

Published
2002

17. Quelle inscription pour des enfants placés ?

Author

Jean-Pierre Kieffer and Béatrice Herpin-Giret

Subjects
Sociology and Political Science, Developmental and Educational Psychology, Education
Abstract

Des professionnels de l’education temoignent des liens tisses avec des enfants et des jeunes passes par un service de placement familial et aujourd’hui adultes. L’attention portee par ces professionnels a la qualite des relations avec ces sujets adultes devoile ici toute son importance, notamment en termes d’inscription de la continuite d’un parcours de vie.

Published
2008

19. Survival and prognosis factors in systemic sclerosis data of a French multicenter cohort, systematic review, and meta-analysis of the literature

Author

Christian Agard, Luc Dauchet, M. R. Pokeerbux, Eric Hachulla, Luc Mouthon, Yannick Allanore, Jonathan Giovannelli, Arsène Mekinian, Jean-Christophe Lega, Patrick Jego, Boris Bienvenu, Sabine Berthier, D. Launay, Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Université Sorbonne Paris Cité (USPC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Cochin], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de médecine interne et immunologie clinique (SOC 1) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Grants or financial supporters: none.Financial support or other benefits from commercial sources: none, French National Scleroderma Cohort coauthors: Zahir AMOURA Z, Olivier AUMAITRE, Eric AUXENFANTS, Marie-Hélène BALQUET, Cristina BELIZNA, Alice BEREZNE A, Bernard BONNOTTE, Pascal CATHEBRAS, Emmanuel CHATELUS, Joël CONSTANS, Vincent COTTIN V, Gonzalo DE LUNA G, Robin DHOTE, Elisabeth DIOT, Olivier FAIN, Anne-Laure FAUCHAIS, Yves FRANCES, Jean-Gabriel FUZIBET, Jean-Baptiste GAULTIER, Tiphaine GOULENOK, Brigitte GRANEL, Jean-Robert HARLE, Pierre-Yves HATRON, Arnaud HOT, Bernard IMBERT, Jean-Emmanuel KAHN, Gilles KAPLANSKI, Pierre KIEFFER, Noémie LE GOUELLEC, Alain LE QUELLEC, Olivier LIDOVE, Nadine MAGY-BERTRAND, François MAURIER, Sylvain PALAT, Thomas PAPO, Jean-Louis PENNAFORTE, Jacques POUCHOT, Grégory PUGNET, Thomas QUEMENEUR, Viviane QUEYREL, Laurent SAILLER, Thierry SCHAEVERBEKE, Marie-Elise TRUCHETET, Denis WAHL., Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Lille Inflammation Research International Center (LIRIC), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement (Inserm U1167 - RID-AGE - Institut Pasteur), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], and CHU Saint-Antoine [APHP]

Subjects
Adult, Male, medicine.medical_specialty, Vital capacity, lcsh:Diseases of the musculoskeletal system, Survival, Kaplan-Meier Estimate, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Multicenter Studies as Topic, Medicine, 030212 general & internal medicine, Aged, 030203 arthritis & rheumatology, Scleroderma, Systemic, business.industry, Incidence, Mortality rate, Hazard ratio, Interstitial lung disease, Middle Aged, Prognosis factors, Prognosis, medicine.disease, 3. Good health, Survival Rate, Meta-analysis, Standardized mortality ratio, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Scleroderma, Diffuse, Cohort, Systemic sclerosis, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, lcsh:RC925-935, business, Research Article, Cohort study
Abstract

Background Data on survival and prognosis factors in incident cohorts are scarce in systemic sclerosis (SStc). To describe survival, standardized mortality ratio (SMR), and prognosis factors in systemic sclerosis (SSc), we analyzed a multicenter French cohort of incident patients and performed a systematic review of the literature and meta-analysis. Methods A multicenter, French cohort study was conducted between January 1, 2000, and December 31, 2013. Patients were followed-up until July 1, 2016. A systematic review of the literature was carried out in MEDLINE and EMBASE up to July 2017. Meta-analysis was performed using all available data on SMR and hazard ratios of prognosis factors. Results A total of 625 patients (493 females, 446 lcSSc) were included. During the study period, 104 deaths (16.6%) were recorded and 133 patients were lost to follow-up. Overall survival rates at 1, 3, 5, and 10 years from diagnosis were 98.0%, 92.5%, 85.9%, and 71.7% respectively in the French cohort. Overall SMR was 5.73 (95% CI 4.68–6.94). Age at diagnosis > 60 years, diffuse cutaneous SSc, scleroderma renal crisis, dyspnea, 6-min walking distance (6MWD), forced vital capacity 8 mg/l were associated with a poorer survival after adjustment. Eighteen studies (11,719 patients) were included in the SMR meta-analysis and 36 studies (26,187 patients) in the prognosis factor analysis. Pooled SMR was 3.45 (95%CI 3.03–3.94). Age at disease onset, male sex, African origin, diffuse cutaneous SSc, anti-Scl70 antibodies, cardiac and renal involvement, interstitial lung disease, PH, and malignancy were significantly associated with a worse prognosis. Anti-centromere antibodies were associated with a better survival. Conclusions Overall, our study highlights a high mortality rate in SSc patients and confirms previously described prognosis factors related to skin extension and organ involvement while identifying additional prognosis factors such as autoantibody status, telangiectasia, 6MWD, and valvular disease. Electronic supplementary material The online version of this article (10.1186/s13075-019-1867-1) contains supplementary material, which is available to authorized users.

Published
2019

20. Intégration par la gestion des compétences dans les groupements d'entreprises

Author

Boucher, Xavier, Boudarel, Marie-Reine, Mnemoi, G., Equipe : Modélisation et Evaluation des Systèmes PROductifs Distribués (MESPROD-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-UR LSTI, Département Performance Industrielle et Environnementale des Systèmes et des Organisations (PIESO-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Henri Fayol, Méthodes d'Analyse Stochastique des Codes et Traitements Numériques (GdR MASCOT-NUM), Centre National de la Recherche Scientifique (CNRS), Jean-Claude Bertrand, Jean-Pierre Kieffer, and Breuil, Florent

Subjects
[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2001

21. Intégration de la gestion des compétences dans le génie industriel : acquis et perspectives

Author

Boucher, Xavier, Harzallah, M., Equipe : Modélisation et Evaluation des Systèmes PROductifs Distribués (MESPROD-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-UR LSTI, Département Performance Industrielle et Environnementale des Systèmes et des Organisations (PIESO-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Henri Fayol, Méthodes d'Analyse Stochastique des Codes et Traitements Numériques (GdR MASCOT-NUM), Centre National de la Recherche Scientifique (CNRS), Jean-Claude Bertrand, Jean-Pierre Kieffer, and Breuil, Florent

Subjects
[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2001

22. Un cadre de modélisation des trajectoires d'évolution des groupements d'entreprises

Author

Burlat, Patrick, Vila, D., Besombes, Béatrix, Deslandres, Véronique, Département Organisation et Modélisation des Systèmes Industriels (OMSI-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre G2I, Equipe : Modélisation et Evaluation des Systèmes PROductifs Distribués (MESPROD-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-UR LSTI, Laboratoire d'Analyse des Signaux et des Processus Industriels (LASPI), Université Jean Monnet [Saint-Étienne] (UJM), Laboratoire d'Informatique pour l'Entreprise et les Systèmes de Production (LIESP), Université Lumière - Lyon 2 (UL2)-École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Jean-Claude Bertrand, Jean-Pierre Kieffer, and Breuil, Florent

Subjects
[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results